Elusys Presents Data from Anthim® Anthrax Anti-toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day

Media Center PRESS RELEASE 2009 ELUSYS PRESENTS DATA FROM ANTHIM® ANTHRAX ANTI-TOXIN STUDIES AT THE HHS STAKEHOLDERS WORKSHOP 2009 & BARDA INDUSTRY DAY Anthim Dramatically Improves Survival in Primates with Symptoms of Anthrax Disease Pine Brook, NJ – December 7, 2009 – Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the […]

Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement

Media Center PRESS RELEASE 2009 ELUSYS THERAPEUTICS AND LONZA ENTER INTO MANUFACTURING AGREEMENT Pine Brook, NJ (USA) and Basel (Switzerland) – 16 June 2009 – Elusys Therapeutics and Lonza Sales AG entered into an agreement for the production of Anthim™, a therapeutic monoclonal antibody in late stage development for the treatment of anthrax infection. Under […]